Skip to main navigation

Top

Skip to main content

About Us

About Us
Rare Diseases

Rare Defined Diseases
Pipeline

Pipeline
Our Medicines

Our Medicines
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Apr 29, 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Read More

PDF Version

Apr 06, 2026

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Read More

PDF Version

Mar 31, 2026

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Read More

PDF Version

Mar 02, 2026

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Read More

PDF Version

Feb 12, 2026

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Read More

PDF Version

Jan 26, 2026

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Read More

PDF Version

Jan 12, 2026

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Read More

PDF Version

Jan 05, 2026

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Read More

PDF Version

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on X.

Connect on LinkedIn

Follow us on X

Contact
About Us
Partner Opportunities
Careers

Agios Pharmaceuticals, Inc. © 2026

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use